Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Abstract Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which...

Full description

Saved in:
Bibliographic Details
Main Authors: Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Erkan Buket Ozmarasalı, Yasemin Sagdıc Karateke, Teoman Sakalar, Sendag Yaslikaya, Ilknur Deliktas Onur, Goncagul Akdag, Ali Ogul, Murad Guliyev, Elif Sahin, Ebru Engin Delipoyraz, Ali Alkan, Okan Aydın, Nurullah Ilhan, Ozkan Alan, Sinem Akbas, Yaprak Cağlar, Ali Kaan Guren, Nadiye Sever, Halil Ibrahim Ellez, Fatih Selcukbiricik, Mustafa Muhammed Atcı, Ahmet Bilici, Nebi Serkan Demirci, Tugba Basoglu, Cengiz Karacin, Ismail Oguz Kara, Bulent Yıldız, Turkkan Evrensel, Mustafa Karaca, Omer Dizdar, Elif Atag, Alpaslan Ozgun, Osman Kostek
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Adjuvant therapy
Dabrafenib plus trametinib
Chemotherapy
Immune checkpoint inhibitors
Melanoma
Survival outcomes
Online Access:https://doi.org/10.1038/s41598-025-87553-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-87553-z

Similar Items